Theraclion to Host Conference Call to Discuss First Immuno-Oncology Metastatic Breast Cancer Trial Combining Pembrolizumab and Echotherapy

information fournie par Boursorama •23/08/2017 à 15:00

Theraclion to Host Conference Call to Discuss First Immuno-Oncology Metastatic Breast Cancer Trial Combining Pembrolizumab and Echotherapy

David Brenin, M.D., breast surgeon at the University of Virginia School of Medicine and co-lead investigator, will discuss the trial

Malakoff - FRANCE, August 22, 2017 - THERACLION (Alternext, FR0010120402 - ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that it will host a conference call and webcast to discuss the recently FDA-authorized clinical trial combining the checkpoint inhibitor, pembrolizumab, with Theraclion’s echotherapy (also known as High Intensity Focused Ultrasound, HIFU) in women with metastatic breast cancer. David Brenin, M.D., a co-lead investigator of the trial will describe the clinical trial.
Event: Theraclion Echotherapy + Immuno-Oncology Combination Clinical Trial
Date: Thursday, September 7, 2017
Time:11 a.m. EDT

The dial-in numbers for the call are +1-877-718-5107 (United States) and +1-719-325-4917(International). The conference ID number is 9476148. A live webcast of the conference call will be available on the investor relations page of the Theraclion corporate website at www.theraclion.com. The webcast will also be archived for one year on the investor relations page of the company’s website.